United Therapeutics Corporation

UTHR

Held by 7 specialist biotech funds

High Convergence

7 funds opened new positions. Next phase2 readout: Jul 2010. Short interest: 6.0% of float.

BiotechnologyCEO: Martine A. RothblattIPO: 1999Website ↗

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Catalysts

Phase 3Q3 2008Oral treprostinil (UT-15C) sustained release tabletsPulmonary HypertensionNCT00325442

Primary: Six Minute Walk Distance (6MWD) (Baseline and 16 Weeks)Enrollment:354/354Sites: 72RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2010Muscle Loss, Muscle AnabolismNCT01366924

Primary: Change in muscle protein synthesis after exercise or exercise with amino acid supplementation. (An average change over a 210 minute recovery period from a 60 minute endurance exercise session)Enrollment:23/23Sites: 2RANDOMIZED, DOUBLE, BASIC_SCIENCE

Phase 2NegativeQ3 2010MAb-3F8Primary Refractory NeuroblastomaNCT00969722

Primary: To compare the proportion of patients achieving a complete bone marrow response measured by an absence of histological evidence of bone marrow disease and by MIBG scan after two cycles of treatment. (two years)Enrollment:1/1Sites: 15RANDOMIZED, TREATMENT

Phase 2Q3 2011LapatinibBreast CancerNCT00299286

Primary: Changes in Ki67 after short term treatment with lapatinib. (11-14 days after treatment)Enrollment:121/121Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2014DoxycyclineAdvanced Malignant Neoplasm, Dermatologic ComplicationNCT01867294

Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) (At 8 weeks)Enrollment:19/19Sites: 5RANDOMIZED, SINGLE, SUPPORTIVE_CARE

Phase 2Q2 2018Oral treprostinilPulmonary Hypertension, Pulmonary FibrosisNCT02603068

Primary: Change in pulmonary vascular resistance (PVR) (Baseline to Week 16)0Sites: 7RANDOMIZED, TREATMENT

Phase 2Q1 2019PembrolizumabMetastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal CarcinomaNCT02949219

Primary: Overall Confirmed Response Rate (1 year (up to 18 cycles))Enrollment:41/41Sites: 8NA, TREATMENT

Phase 2Q3 2019Brentuximab VedotinAnn Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin LymphomaNCT02758717

Primary: Overall Metabolic Response Rate (Up to 8 cycles of treatment (approximately 29 weeks))Enrollment:46/46Sites: 9NA, TREATMENT

Phase 3NegativeQ4 2019Adenocarcinoma of the ProstateNCT03327662

Phase 3PositiveQ4 2019Inhaled TreprostinilPulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and EmphysemaNCT02630316

Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16)Enrollment:326/326Sites: 97RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2020SelumetinibMetastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland CarcinomaNCT02393690

Primary: Response at 6 Months (At 6 months)Enrollment:60/60Sites: 11RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2021Eribulin MesylateBreast Adenocarcinoma, HER2/Neu Negative, Invasive Breast CarcinomaNCT02037529

Phase 2Q1 2021FluorouracilMetastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction AdenocarcinomaNCT03337087

Primary: Number of Participants With Dose Limiting Toxicities (Phase I) (Up to 28 days from start of treatment)Enrollment:18/18Sites: 3NA, TREATMENT

Phase 3Q2 2021Fulvestrant 500mgBreast Neoplasm FemaleNCT03447132

Phase 3Q3 2021UT-15C (treprostinil diolamine)Pulmonary Arterial HypertensionNCT01560637

Phase 2Q3 2021CarboplatinRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaNCT02628405

Primary: Overall Response Rate (Phase II) (At 42 days (after 2 courses) of treatment)Enrollment:30/30Sites: 12NA, TREATMENT

Phase 2Q4 2021Bladder CancerNCT02447549

Primary: Proportion of participants meeting predefined radiotherapy dose constraints in DART group (4-6 weeks from randomisation)Enrollment:345/345Sites: 49RANDOMIZED, TREATMENT

Phase 2Feb 10, 2022177Lu-J591Prostate CancerNCT00859781

Primary: Proportion of Participants Free of Radiographically Evident Metastases From Baseline to 18 Months After Study Drug Administration (Baseline and 18 months after study drug administration)Enrollment:55/55Sites: 9RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2022UI022 or UI023 and co-administration of matching placeboPeripheral Arterial DiseaseNCT07600385

Phase 2Q3 2022CyclophosphamideBilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7NCT03012100

Primary: Disease-free survival (Through study completion (average of 5 years))Enrollment:280/280Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2022Yogurt smoothie with BB-12Metabolic SyndromeNCT03418857

Primary: Change from baseline in inflammatory markers (At baseline before intervention period 1, at endpoint of intervention period 1 (week 4), at baseline before intervention period 2 (week 8), at endpoint after intervention period 2 (week 12))Enrollment:Target 40Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Nov 15, 2022Critical Illness, Wounds and Injury, Disease AttributesNCT04534972

Primary: Supplemental Oxygen Free Days (SOFD) (up to 28 days)Enrollment:Target 2,000Sites: 6RANDOMIZED, TREATMENT

Phase 3Nov 15, 2022Critical Illness, Wounds and Injury, Disease AttributesNCT04534959

Primary: Supplemental Oxygen Free Days (SOFD) (up to 28 days)Enrollment:Target 6,000Sites: 8RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2022Inhaled treprostinil solutionPulmonary Hypertension, Chronic Obstructive Pulmonary DiseaseNCT03794583

Phase 2Q1 2023UB-421HIV-1 InfectionNCT05056974

Phase 2Feb 17, 2023EnzalutamideBreast CancerNCT02955394

Primary: Number of Patients With a PEPI Score Equal to Zero at Post Treatment (16 Weeks)Enrollment:61/61Sites: 3RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2023Abiraterone AcetateMetastatic Castration Resistant Prostate CancerNCT04458311

Phase 2Q3 2023CetuximabBRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal AdenocarcinomaNCT04117945

Primary: Overall Survival (OS) (20 months)Enrollment:22/22Sites: 15RANDOMIZED, TREATMENT

Phase 2Q4 2023PanitumumabMetastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal AdenocarcinomaNCT03992456

Primary: Overall Survival (OS) (2 years)Enrollment:12/12Sites: 18RANDOMIZED, TREATMENT

Phase 2Jan 23, 2024[18F]PSMA-1007 InjectionProstate Cancer, Prostate Adenocarcinoma, Prostate NeoplasmNCT04053842

Primary: Pathologic Validation and Modeling (4 years)Enrollment:Target 45Sites: 1NA, DIAGNOSTIC

Phase 2Q1 2024PalmidrolChemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid NeoplasmNCT05246670

Primary: Mean Change in Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) Score (8 weeks)Enrollment:88/88Sites: 10RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 3Q2 2024Aromatase InhibitorsBreast CancerNCT02338310

Phase 2Jun 25, 2024N-Acetyl cysteineNeurofibromatosis 1NCT04481048

Phase 2Q2 2024Doxazosin Mesylate, Extended ReleaseStress Disorders, Post-TraumaticNCT03339258

Phase 2Q3 2024Leukocyte-Poor Platelet Rich Plasma (LP-PRP)Osteoarthritis, KneeNCT04205656

Phase 2Q3 2024PaclitaxelClinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8NCT04660760

Phase 2Q3 2024Placebo InfusionBrain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)NCT02525432

Phase 2Q3 2024AcalabrutinibMantle Cell LymphomaNCT04626791

Phase 2Aug 13, 2024CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8NCT05242965

Phase 2Aug 26, 2024MetforminC9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal DementiaNCT04220021

Phase 3Sep 30, 2024IbuprofenPatent Ductus Arteriosus After Premature BirthNCT05011149

Phase 2Q3 2024CarfilzomibRecurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaNCT04756401

Phase 2Oct 31, 2024FisetinFemoroacetabular ImpingementNCT05025956

Phase 2Feb 6, 2025PembrolizumabBreast CancerNCT03366844

Phase 2Jul 1, 2025TreprostinilIschemia Reperfusion Injury, Delayed Graft FunctionNCT04005469

Phase 2Q3 2025Brentuximab VedotinAnn Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin LymphomaNCT03233347

Phase 3Jul 9, 2025RegorafenibGastro-Oesophageal CancerNCT04879368

Phase 2NegativeQ3 2025IpilimumabBCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular CarcinomaNCT05199285

Phase 2Sep 12, 2025CarboplatinRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaNCT04387227

Phase 2Q3 2025CT-011Multiple MyelomaNCT01067287

Phase 2Q3 2025Cyclobenzaprine HClAcute Stress Reaction, Acute Stress Disorder, Neurocognitive FunctionNCT06636786

Phase 2Oct 1, 2025CabozantinibAdvanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8NCT05361720

Phase 2Q4 2025DurvalumabStage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8NCT05194293

Phase 2Q4 2025UBT251 Injection 2.0 mg and UBT251 Injection PlaceboType 2 Diabetes Mellitus (T2DM)NCT07163624

Phase 2Dec 22, 2025DC1 VaccineBreast Cancer Female, Breast Cancer, Male, Breast Cancer Stage INCT03384914

Phase 2Q4 2025UBT251 Injection 2.0 mg and UBT251 Injection PlaceboObesity &Amp; OverweightNCT07177469

Phase 2Dec 31, 2025LofexidinePost Traumatic Stress Disorder, Opioid-use DisorderNCT04360681

Phase 2Q4 2025AtezolizumabLocally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8NCT05168163

Primary: Overall survival (OS) (From randomization to death from any cause, assessed up to 3 years)Enrollment:Target 122Sites: 16RANDOMIZED, TREATMENT

Phase 2Q4 2025Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)Hormonal Receptors Positive, HER2 Negative, Advanced Breast CancerNCT05190094

Phase 2Q4 2025Levoleucovorin CalciumAutism Spectrum Disorder, Language DisordersNCT04060017

Phase 2Q4 2025MultiStemTrauma, Adult Stem CellsNCT04533464

Phase 2Jan 1, 2026TecovirimatSmallpoxNCT04957485

Phase 2Jan 1, 2026umbilical cord-derived mesenchymal stromal cells (UC-MSCs)Ischemic Heart DiseaseNCT06145035

Phase 2Q1 2026AM3101Meniscus TearNCT05560477

Phase 2Mar 30, 2026Abdominal TraumaNCT06065202

Phase 2Mar 31, 2026Iodine-124Thyroid CancerNCT06961084

Phase 2Q1 2026177Lu-PSMA-617Metastatic Hormone Naive Prostate CancerNCT04343885

Phase 2Mar 31, 2026Ibrutinib 560 mgMantle Cell LymphomaNCT04802590

Phase 2Q1 2026ipatasertibSolid Tumor, Glioblastoma Multiforme, Prostate Cancer MetastaticNCT03673787

Phase 2Apr 30, 2026cyclophosphamideMalignant Pleural Disease, Mesothelioma, MetastasesNCT02414269

Phase 2May 29, 2026rF1V-1018Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia PestisNCT07207408

Primary: Anti-rF1V antibody level (4 weeks after final study vaccine)Enrollment:Target 148Sites: 3RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2026Spinal Cord InjuriesNCT04782947

Phase 2Jun 1, 2026Clemastine FumarateMultiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary ProgressiveNCT05359653

Phase 2Jun 1, 2026KetamineMultiple Sclerosis FatigueNCT05378100

Phase 3Jun 30, 2026Lopinavir-RitonavirSevere Acute Respiratory SyndromeNCT04381936

Phase 2Jun 30, 2026LinaclotideColorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8NCT03796884

Phase 3Q2 2026Autism Spectrum DisorderNCT05268796

Phase 3Q2 2026UB-421HIV-1 InfectionNCT04406727

Phase 3Q2 2026Inhaled TreprostinilIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary FibrosisNCT04905693

Phase 2Q2 2026Enzalutamide 40mgMetastatic Castration-Resistant Prostate Cancer (m CRPC)NCT06126731

Phase 2Jun 30, 2026DexamethasoneVoice Change, HypocalcemiaNCT05732883

Phase 2Jul 1, 2026cP12Thermal BurnsNCT06814717

Phase 2Q3 2026Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain InjuryNCT06073886

Phase 2Q3 2026Recombinant human growth hormoneGulf War Syndrome, Adult Growth Hormone DeficiencyNCT05355272

Phase 3Q3 2026Tobramycin InjectionWound Infection, Fractures, Open, Surgical Site InfectionNCT04964947

Phase 2Q3 2026Testosterone cypionateCastration Resistant Metastatic Prostate CancerNCT04363164

Phase 3Q3 2026Tranexamic AcidSpinal Injuries, Spinal DeformityNCT02314988

Phase 2Jul 31, 2026Infusion of 5 mg/kg InfliximabAcute PancreatitisNCT03684278

Phase 2Aug 1, 2026AmputationNCT04839497

Phase 3Q3 2026BupivacainePostoperative PainNCT06989866

Phase 3Aug 15, 2026RifampicinSevere Acute Malnutrition, HIV, Comorbidities and Coexisting ConditionsNCT05994742

Phase 2Aug 15, 2026pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA VaccineAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8NCT04329065

Phase 2Aug 31, 2026Neuromuscular Blocking AgentsRespiratory Distress Syndrome, AdultNCT04545424

Phase 2Q3 2026CeralasertibGynaecological CancersNCT04065269

Phase 2Q3 2026AspirinVestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2NCT03079999

Phase 2Q3 2026SemaglutideCardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFp EF), ObesityNCT05371496

Phase 2Sep 1, 2026SildenafilScleroderma, Mildly Elevated Pulmonary PressuresNCT04797286

Phase 2Sep 28, 2026Mesenchymal Stromal CellsCorneal UlcerNCT05705024

Phase 2Sep 29, 2026BXCL501 (dexmedetomidine HCl)Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress DisorderNCT06943404

Phase 2Sep 30, 2026BoNT ATraumatic Brain InjuryNCT06293300

Phase 2Sep 30, 2026Breast Cancer RecurrentNCT05464082

Phase 3Sep 30, 2026Standard of carePost Operative Surgical Site InfectionNCT04678154

Phase 3Q3 2026Standard of Care PO (oral) antibioticsInfections, Infected Wound, Nonunion of FractureNCT05699174

Phase 2Oct 1, 2026EvolocumabMetastatic Renal Cell CarcinomaNCT06284564

Phase 2Q4 2026Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung CancerNCT07104630

Phase 2Q4 2026BevacizumabRecurrent Glioblastoma, Recurrent WHO Grade 4 GliomaNCT06160206

Primary: Overall survival (OS) (Time until death from any cause, assessed up to 9 months after registration)Enrollment:Target 134Sites: 3RANDOMIZED, TREATMENT

Phase 2Nov 30, 2026SiltuximabSchwannomatosis, Schwannomas, Pain, ChronicNCT05684692

Phase 2Dec 1, 2026Advair HFAAltitude EdemaNCT06040268

Phase 2Dec 30, 2026Anti-CD40 Agonist Monoclonal Antibody CDX-1140Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous AdenocarcinomaNCT05231122

Phase 3Q4 2026RalinepagPAH, Pulmonary Hypertension, Pulmonary Arterial HypertensionNCT03683186

Phase 2Q4 2026AZD6738Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDNCT03740893

Phase 2Q4 2026ACIT-1Cancer, NeoplasmsNCT03096093

Phase 2Q4 2026pantoprazolePostoperative Nausea and VomitingNCT06488001

Phase 3Q4 2026600 mg IbuprofenTibial Fractures, PainNCT07006675

Phase 2Q4 2026DegarelixProstate CancerNCT04989946

Phase 2Q4 2026CarboplatinHormone Refractory Prostate CancerNCT02955082

Phase 2Dec 31, 2026Pembrolizumab (200mg IV for 30 minutesBreast CancerNCT03804944

Phase 2Jan 4, 2027DFMOProstate CancerNCT06059118

Phase 2Jan 14, 2027Tranexamic AcidAnterior Cruciate Ligament ReconstructionNCT03552705

Phase 2Q1 2027[11C]CPPC PET ligandALSNCT05602142

Phase 2Feb 26, 2027BrexanoloneAlcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)NCT06580444

Phase 2Q1 2027N-acetyl cysteineMultiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary ProgressiveNCT05122559

Phase 2Q1 2027CannabidivarinAutism Spectrum DisorderNCT03202303

Phase 3Q1 2027Sickle Cell DiseaseNCT05392894

Phase 2Q1 2027Calcium GluconateTrauma, HemorrhageNCT05958342

Phase 2Mar 31, 2027Ropivacaine injectionStress Disorders, Post-TraumaticNCT05889741

Phase 2Q2 2027allogeneic human mesenchymal stem cells (hMSCs)Non-ischemic Dilated CardiomyopathyNCT04476901

Phase 3Apr 30, 2027NicotinomideGlaucoma, Open-AngleNCT05405868

Phase 3Q2 2027PaclitaxelSquamous Cell Carcinoma of the Penis, Usual TypeNCT02305654

Primary: Overall survival (up to 5 years)Enrollment:Target 200Sites: 17RANDOMIZED, TREATMENT

Phase 3May 31, 2027Pembrolizumab 25 MG/ML [Keytruda]Lung Cancer, Nonsmall CellNCT05085028

Phase 2Q2 2027UBT251Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT07145151

Phase 2Jun 15, 2027Anti-HER2/HER3 Dendritic Cell VaccineAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast CarcinomaNCT04348747

Phase 2Q2 2027Niraparib oral capsuleOvarian Cancer RecurrentNCT05990192

Phase 2Jul 1, 2027Inhaled Treprostinil (Tyvaso Nebulizer)COPD (Chronic Obstructive Pulmonary Disease), HypoxemiaNCT07037836

Phase 2Jul 31, 2027PembrolizumabPancreatic CancerNCT05093231

Primary: Objective Response Rate (ORR) (Through study completion, an average of 2 years)Enrollment:Target 20Sites: 13NA, TREATMENT

Phase 3Jul 31, 2027IsoniazidTuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph NodeNCT06253715

Phase 2Aug 31, 20271. Intranasal oxytocin sprayAutism Spectrum Disorder, Bone HealthNCT05754073

Phase 2Sep 1, 2027Palbociclib 125Mg TabER+ Breast Cancer, HER2-negative Breast CancerNCT04985266

Phase 3Q3 2027UBT251 Injection 2.0 mgType 2 DiabetesNCT07659574

Phase 3Q3 2027Diabetic Foot Ulcer (DFU)NCT07488247

Primary: Number of adverse event experienced by participants (03 months)Enrollment:Target 300Sites: 1RANDOMIZED, TREATMENT

Phase 2Q3 2027Angiotensin (1-7)Traumatic Brain InjuryNCT06282965

Phase 2Oct 1, 2027NTX-001Peripheral Nerve InjuriesNCT04789044

Phase 2Oct 30, 2027177Lu girentuximabAdvanced Cancer, Clear Cell Renal Cell CarcinomaNCT05663710

Phase 2Q4 2027225Ac-J591Prostate CancerNCT04946370

Phase 2Q4 2027Metformin + Standard of CareFocal Segmental GlomerulosclerosisNCT06090227

Phase 3Q4 2027PlaceboProgressive Pulmonary Fibrosis, Interstitial Lung DiseaseNCT05943535

Phase 2Dec 2, 2027autologous skin fibroblastsWounds and InjuriesNCT01964859

Phase 3Q4 2027PharmaNord Bio-Quinone Active CoQ10 Gold 100mgGulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory ChainNCT06515184

Phase 2Q4 2027Tesamorelin 2 Milligrams (MG)Peripheral Nerve InjuriesNCT03150511

Phase 3Dec 31, 2027Direct-Acting Oral Anticoagulants (used as per local standard practice)Traumatic Intracranial HaemorrhageNCT06322953

Phase 3Dec 31, 2027Cladribine (MAVENCLAD®)Advanced Multiple Sclerosis, Progressive Multiple SclerosisNCT04695080

Phase 3Q1 2028UBT251 Injection 2.0 mg groupType 2 DiabetesNCT07653477

Phase 2Mar 1, 2028Psilocybin (Usona Institute)Spinal Cord Injury, Depression - Major Depressive Disorder, VeteranNCT07251491

Phase 2Apr 1, 2028Autologous Skin FibroblastsAmputation, Skin Wound, Stem CellNCT03947450

Phase 2Jun 4, 2028Colorectal Cancer, Bladder CancerNCT06528990

Phase 2Q2 2028Hydrogen PeroxideBreast CancerNCT03946202

Phase 3Q2 2028Prostate CancerNCT05613023

Phase 3Q3 2028Ketamine HydrochlorideTraumatic InjuryNCT05437575

Phase 2Aug 31, 2028Atorvastatin CalciumTraumatic Brain InjuryNCT05826912

Phase 2Sep 1, 2028Enfortumab vedotinMetastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial CarcinomaNCT07221942

Phase 3Q3 2028Autonomic Nervous System Disease, Concussive Injury, Mild Traumatic Brain InjuryNCT07071350

Phase 2Sep 30, 2028Propranolol HydrochloridePostoperative Chylothorax, Congenital Heart Disease, Open Heart SurgeryNCT06833320

Phase 2Oct 1, 2028RoginolisibLeukemia, Relapsed Leukemia, Chronic Lymphocytic LeukemiaNCT06644183

Phase 2Q4 2028L-citrullinePost Deployment Related Asthma, AsthmaNCT05259904

Phase 2Q4 202810 GE XenokidneyESRD (End-Stage Renal Disease), Kidney Transplantation, XenotransplantationNCT06878560

Phase 2Q4 2028bomedemstatMyelofibrosisNCT07424950

Phase 2Q4 2028PropranololAutism Spectrum Disorder, Challenging Behaviour, AggressionNCT07091279

Phase 2Q4 2028DexamethasoneLymphoblastic LeukemiaNCT05848687

Phase 2Dec 31, 2028Carboplatin plus PaclitaxelOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CarcinomaNCT07023484

Phase 3Q4 2028Venetoclax 400Acute Myeloid LeukemiaNCT07075016

Phase 2Dec 31, 2028Cord blood transplantation + conditioning + granulocytes of variable days according to study designAcute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, HematopoieticNCT07372885

Phase 2Q4 2028Universal Donor (UD) TGFβi NK CellsNeuroblastomaNCT06450041

Phase 2Q1 2029PaxalisibMalignant Primary Gliomas, Glioblastoma Multiforme (GBM)NCT07391215

Phase 2Mar 1, 2029PT150PTSD - Post Traumatic Stress DisorderNCT07187011

Phase 3Mar 29, 2029Hematologic MalignanciesNCT07186192

Phase 2Mar 30, 2029FluorouracilClinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8NCT05651594

Phase 2Q1 2029GGTA1 KO ThymokidneyESRD (End-Stage Renal Disease), Kidney Transplantation, XenotransplantationNCT07224763

Phase 2Q2 2029Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease PatientsNCT07071935

Phase 2Jun 30, 2029Long COVID, Long COVID Syndrome, Long COVID-19 SyndromeNCT06940609

Phase 2Q3 2029AvutometinibGlioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-MutantNCT06630260

Phase 2Q4 2029SX-682Metastatic Castrate-Resistant Prostate Cancer (m CRPC)NCT07002320

Primary: Biologically active and tolerable dose range (From start of treatment to end of Cycle 2 Day 1 (each cycle is 28 days))Enrollment:Target 78Sites: 4NON_RANDOMIZED, TREATMENT

Phase 3Dec 13, 2029RevumenibAcute Myeloid Leukemia, AdultNCT06652438

Phase 2Q4 2029LenalidomideRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaNCT05910801

Phase 2Q4 2029EpcoritamabDiffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaNCT06238648

Phase 2Q1 20303,4-Methylenedioxymethamphetamine (MDMA)Post Traumatic Stress DisorderNCT07288151

Phase 3Q1 2030Valproic Acid (VPA)Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain InjuryNCT07166393

Phase 2Q1 2030UI-102Advanced CancerNCT07605962

Phase 3Q2 2030PlasmaBurn Injury, Thermal BurnNCT07212998

Phase 3Q2 2030CHIKV VLP vaccineChikungunya VirusNCT07467707

Phase 2Q3 2030UBT251Obesity &Amp; Overweight, Chronic Kidney DiseaseNCT07134335

Phase 2Jul 31, 2030Radiation: 131I-MIBGNeuroblastomaNCT07261241

Phase 3Q4 2030AbemaciclibBreast Cancer FemaleNCT04584853

Phase 2Nov 1, 2030Selpercatinib MonotherapyDifferentiated Thyroid Cancer, Pediatric Cancer, CancerNCT06458036

Phase 2Mar 30, 2031Abiraterone acetateProstate Cancer (Adenocarcinoma), Metastatic Prostate CancerNCT06616597

Phase 3Q2 2031PlaceboParkinsons Disease (PD)NCT07207057

Phase 3Jun 1, 2031paclitaxelGerm Cell Tumor, Teratoma, ChoriocarcinomaNCT02375204

Phase 2Aug 1, 2031IpilimumabLocally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell CarcinomaNCT06866262

Phase 2May 31, 2032ZumsemetinibHormone Receptor Positive HER-2 Negative Metastatic Breast CancerNCT06374459

Phase 3Dec 20, 2033Cervical Carcinoma, Adenocarcinoma, Adenosquamous CarcinomaNCT05581121

United Therapeutics Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research